Saturday 17 October 2026
Export ALDX’s income statement to Excel — free account
Aldeyra Therapeutics, Inc.
ALDX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.8%, free cash flow grew 46.1% and total debt rose 1.33%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.70
0.04
−5.41%
Follow ALDX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
10.93 | 13.11 | 11.18 | 5.82 | 6.69 | 19.77 | 11.79 | 6.64 | 5.59 | 2.58 |
Net Debt/EBITDA |
1.28 | 1.87 | 2.35 | 0.93 | 1.75 | 3.83 | 2.54 | 3.00 | 1.40 | 1.52 |
Debt/Assets |
5.23% | 3.03% | 0.00% | 19.54% | 18.11% | 6.75% | 8.73% | 10.21% | 14.37% | 21.16% |
Debt/Equity |
0.06 | 0.03 | 0.00 | 0.31 | 0.25 | 0.08 | 0.10 | 0.13 | 0.21 | 0.34 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.81 | 0.86 | 0.77 | 0.74 | 1.00 | 0.74 | 0.91 | 0.81 | 0.77 | 0.99 |
Capex/Depreciation |
(0.04) | (0.13) | 2.45 | 0.04 | 0.00 | (0.03) | (0.08) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(177.21) | (198.14) | (270.43) | (104.46) | (19.13) | (32.27) | (37.00) | (20.66) | (31.21) | (18.51) |
| (80.38%) | (72.95%) | (61.63%) | (90.31%) | (69.81%) | (43.56%) | (34.77%) | (27.73%) | (58.54%) | (58.73%) | |
| (70.05%) | (64.42%) | (55.85%) | (71.31%) | (47.28%) | (36.51%) | (29.93%) | (22.78%) | (44.16%) | (38.32%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(81.70%) | (54.95%) | (44.95%) | (97.46%) | (53.11%) | (26.14%) | (37.44%) | (29.90%) | (65.35%) | (76.97%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(1.34) | (1.21) | (1.39) | (1.66) | (1.10) | (0.79) | (0.97) | (0.51) | (0.73) | (0.56) |
Cash per Share |
2.19 | 2.70 | 4.32 | 2.71 | 2.29 | 4.25 | 2.98 | 2.42 | 1.70 | 1.17 |
Shareholders Equity per Share |
1.91 | 2.49 | 3.99 | 1.77 | 1.75 | 3.81 | 2.59 | 2.03 | 1.19 | 0.74 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.91 | 2.49 | 3.99 | 1.77 | 1.75 | 3.81 | 2.59 | 2.03 | 1.19 | 0.74 |
Free Cash Flow |
(15.16) | (19.25) | (30.12) | (44.99) | (37.49) | (42.56) | (56.65) | (30.33) | (43.21) | (33.35) |
Working Capital |
22.83 | 40.61 | 86.30 | 62.26 | 70.65 | 220.98 | 165.66 | 125.55 | 85.47 | 43.97 |
Capital Expenditures |
(0.01) | (0.02) | (0.26) | (0.01) | — | (0.01) | (0.02) | — | — | — |
Net Current Asset Value |
21.59 | 39.39 | 86.30 | 47.73 | 59.22 | 205.35 | 150.74 | 119.28 | 70.47 | 43.97 |
| Other line items | ||||||||||
Quick Ratio |
10.84 | 12.81 | 11.05 | 5.68 | 6.27 | 19.52 | 11.35 | 6.42 | 5.44 | 2.52 |
Depreciation/Fixed assets |
5.84 | 4.33 | (0.46) | (1.61) | 8.86 | 8.13 | 10.96 | 42.79 | 0.00 | 0.00 |
Cash ROIC |
(31.66%) | (22.95%) | (16.71%) | (33.03%) | (24.59%) | (9.43%) | (16.61%) | (10.92%) | (23.08%) | (25.74%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.33) | (1.21) | (1.38) | (1.66) | (1.10) | (0.79) | (0.97) | (0.51) | (0.73) | (0.56) |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 26.50 | 26.50 | 75.00 | 64.12 | — | — | — |
Average Payables |
0.56 | 0.64 | 2.03 | 1.93 | 0.59 | 0.70 | 0.58 | 0.74 | 0.76 | 0.17 |
Average Assets |
26.70 | 34.68 | 69.63 | 85.30 | 79.44 | 158.24 | 207.21 | 164.81 | 126.47 | 88.33 |
Average Common Equity |
23.26 | 30.63 | 63.11 | 67.35 | 53.80 | 132.62 | 178.37 | 135.40 | 95.40 | 57.63 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Columns are period end dates